Background <p>The optimal timing for initiating direct oral anticoagulants (DOACs) after acute ischemic stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (NVAF) remains uncertain.</p> Objective <p>To determine whether early initiation of DOACs is superior to delayed initiation in preventing new vascular events.</p> Methods <p>This guideline was developed using the GRADE approach and includes a systematic review and meta-analysis of four randomized controlled trials (TIMING, ELAN, OPTIMAS, START) enrolling 6,664 patients. Outcomes were selected via Delphi consensus. Meta-analyses used random-effects models, with certainty of evidence rated per GRADE methodology.</p> Results <p>Early DOAC initiation was associated with a trend toward fewer recurrent ischemic events (RR 0.77, 95% CI 0.52–1.14) and thromboembolic events (RR 0.73, 95% CI 0.50–1.06), with no increase in symptomatic intracranial hemorrhage (RR 0.93, 95% CI 0.44–1.97) or major extracranial bleeding (RR 0.84, 95% CI 0.42–1.69). Certainty of evidence was low due to imprecision. An individual patient data meta-analysis from CATALYST collaboration further supported early treatment in patients with minor to moderate stroke.</p> Recommendations <p>We recommend early DOAC initiation within 4 days in patients with minor to moderate stroke to prevent new vascular events. Early DOAC initiation over delayed treatment is indicated in patients with severe acute ischemic stroke to prevent new vascular events.</p> Conclusion <p>Early DOAC initiation appears safe and potentially more effective than delayed treatment, supporting a shift toward earlier anticoagulation in selected patients with NVAF and recent ischemic stroke.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Timing of anticoagulation therapy in patients with acute ischemic stroke and atrial fibrillation: a GRADE-based expert opinion recommendation

  • Emanuele Spina,
  • Michele Romoli,
  • Maria Giulia Mosconi,
  • Marina Padroni,
  • Isabella Canavero,
  • Marina Mannino,
  • Maria Luisa Zedde,
  • Stefano Ricci,
  • Maurizio Paciaroni

摘要

Background

The optimal timing for initiating direct oral anticoagulants (DOACs) after acute ischemic stroke or transient ischemic attack (TIA) in patients with nonvalvular atrial fibrillation (NVAF) remains uncertain.

Objective

To determine whether early initiation of DOACs is superior to delayed initiation in preventing new vascular events.

Methods

This guideline was developed using the GRADE approach and includes a systematic review and meta-analysis of four randomized controlled trials (TIMING, ELAN, OPTIMAS, START) enrolling 6,664 patients. Outcomes were selected via Delphi consensus. Meta-analyses used random-effects models, with certainty of evidence rated per GRADE methodology.

Results

Early DOAC initiation was associated with a trend toward fewer recurrent ischemic events (RR 0.77, 95% CI 0.52–1.14) and thromboembolic events (RR 0.73, 95% CI 0.50–1.06), with no increase in symptomatic intracranial hemorrhage (RR 0.93, 95% CI 0.44–1.97) or major extracranial bleeding (RR 0.84, 95% CI 0.42–1.69). Certainty of evidence was low due to imprecision. An individual patient data meta-analysis from CATALYST collaboration further supported early treatment in patients with minor to moderate stroke.

Recommendations

We recommend early DOAC initiation within 4 days in patients with minor to moderate stroke to prevent new vascular events. Early DOAC initiation over delayed treatment is indicated in patients with severe acute ischemic stroke to prevent new vascular events.

Conclusion

Early DOAC initiation appears safe and potentially more effective than delayed treatment, supporting a shift toward earlier anticoagulation in selected patients with NVAF and recent ischemic stroke.